Trial reportClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology1990
The effect of intranasal nedocromil sodium on viral upper respiratory tract infections in human volunteers.
Trial report in Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 1990. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity.Nature communications · 2020Pooled it
- The effect of inhaled and intranasal sodium cromoglycate on symptoms of upper respiratory tract infections.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 1996Trial
- Effects of an experimentally induced rhinovirus cold on sleep, performance, and daytime alertness.Physiology & behaviorTrial
- From the "One-Molecule, One-Target, One-Disease" Concept towards Looking for Multi-Target Therapeutics for Treating Non-Polio Enterovirus (NPEV) Infections.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Antibody response to COVID-19 vaccines among workers with a wide range of exposure to per- and polyfluoroalkyl substances.Environment international · 2022Article
- Viral Vector Vaccine Development and Application during the COVID-19 Pandemic.Microorganisms · 2022Review
- Review
- Immunity to SARS-CoV-2 induced by infection or vaccination.Journal of internal medicine · 2022Review
- Reinfection With SARS-CoV-2: Implications for Vaccines.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Review
- Approaches and Challenges in SARS-CoV-2 Vaccine Development.Cell host & microbe · 2020Review
- A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease.medRxiv : the preprint server for health sciences · 2020Article
- Behavioral effects of upper respiratory tract illnesses: a consideration of possible underlying cognitive mechanisms.Behavioral sciences (Basel, Switzerland) · 2012Article
- Lymphocyte and mast cell counts are increased in the nasal mucosa in symptomatic natural colds.Clinical and experimental immunology · 2003Article
- Respiratory viral infections in the elderly.Antiviral research · 1999Review
- Coronavirus pneumonia following autologous bone marrow transplantation for breast cancer.Chest · 1999Article
- Treatment of the common cold.BMJ (Clinical research ed.) · 1998Review
- Problems and prospects of developing effective therapy for common cold viruses.Trends in microbiology · 1997Review
- Cromolyns: treatment for the common cold.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 1996Review
- The Use of Antiallergic and Antiasthmatic Drugs in Viral Infections of the Upper Respiratory Tract.Clinical immunotherapeutics · 1996Article
- The common cold: current therapy and natural history.The Journal of allergy and clinical immunology · 1995Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two studies involving double-blind group comparative trials in human volunteers compared the effects of intranasal nedocromil sodium (2.6 mg active drug per nostril, q.i.d.) with placebo on clinical symptoms and performance impairment associated with the common cold. In the first study volunteers were challenged with rhinoviruses (RV9 and RV14), and in the second study with respiratory coronavirus. In both studies, active and placebo groups of volunteers were demographically similar. Infection rates in both groups were also similar. There were no withdrawals resulting from unusual symptoms related to either treatment. In the rhinovirus study (19, placebo; 20, nedocromil sodium) daily symptom scores and daily mean nasal secretion weights were significantly lower in the nedocromil sodium-treated group. In the coronavirus study (26, placebo; 27, nedocromil sodium) there was little difference in the severity of colds between the active and placebo-treated groups, but trends favoured nedocromil sodium. In both studies the impairment of performance in volunteers who developed a cold was significantly less in those treated with nedocromil sodium than in those treated with placebo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.